|
Cognition Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
3xTg mice, which express an APP/PS1 mutation combined with a tau (P301L) mutation and that develop cognitive deficits at 6 months of age, were subjected to ELF-MF (50Hz, 500μT) exposure or sham exposure daily for 3 months.
|
26945731 |
2016 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
3xTg mice, which express an APP/PS1 mutation combined with a tau (P301L) mutation and that develop cognitive deficits at 6 months of age, were subjected to ELF-MF (50Hz, 500μT) exposure or sham exposure daily for 3 months.
|
26945731 |
2016 |
|
Cognition Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A Morris water maze test was performed and showed that overexpression of miR-361-3p improved cognitive deficits in APP/PS1 mice.
|
31601077 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
|
17600377 |
2007 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice.
|
12544850 |
2003 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Additionally, replenishment of miR-21 restored the cognitive deficits in APP/PS1 mice and prevented pathologic features.
|
28970251 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice.
|
20739292 |
2010 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
As a result, the nanochaperone reduces Aβ burden, attenuates Aβ-induced inflammation, and eventually rescues the cognitive deficits of APP/PS1 transgenic AD mice.
|
31763156 |
2019 |
|
Cognition Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
At 9 months of age, untreated 3×Tg-AD mice vs. wild-type (WT) controls displayed cognitive deficits in behavioral assays and, at 12 months, elevated levels of hippocampal amyloid beta-protein (Aβ), amyloid precursor protein (APP), tau phosphorylation, and pro-inflammatory cytokines.
|
31603034 |
2019 |
|
Cognition Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Because mounting evidence suggests that epileptiform activity may play an important role in the development of AD-related cognitive deficits, we examined whether enhanced cleavage of Navβ2 occurs in APP transgenic mice, and whether it is associated with aberrant neuronal activity and cognitive deficits.
|
23595759 |
2013 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in amyloid precursor protein (APP)/PS1 mice.
|
29860433 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Bis(9)-(-)-Meptazinol, a novel dual-binding AChE inhibitor, rescues cognitive deficits and pathological changes in APP/PS1 transgenic mice.
|
30237878 |
2018 |
|
Cognition Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Both synaptic and cognitive deficits are reproduced in mice double transgenic for amyloid precursor protein (AA substitution K670N,M671L) and presenilin-1 (AA substitution M146V).
|
15578094 |
2004 |
|
Cognition Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
By using biochemical and electrophysiological measures, we found that in a presymptomatic phase, when amyloid plaques have not yet formed and there is no sign of cognitive deficits, the over-expression of full-length APP in the hippocampus of Tg2576 mice altered membrane localization and inhibitory signalling activity of CB<sub>1</sub> receptor, possibly by binding to the receptor and reducing its specific interaction with caveolin-1 and G proteins.
|
29454025 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease.
|
21350020 |
2011 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Chronic diabetic states worsen Alzheimer neuropathology and cognitive deficits accompanying disruption of calcium signaling in leptin-deficient APP/PS1 mice.
|
28467789 |
2017 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Cystatin isolated from chicken egg white, called ovocystatin, has been widely used in the medical and pharmaceutical research due to its structural and biological similarities to human cystatin C. The aim of this study was to assess the effect of administering ovocystatin on the development of dementia-specific cognitive deficits in APP/PS1 transgenic mice.
|
30504006 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer's disease.
|
28275722 |
2017 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
DL0410 ameliorates cognitive deficits in APP/PS1 transgenic mice by promoting synaptic transmission and reducing neuronal loss.
|
31685977 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo.
|
24189446 |
2014 |
|
Cognition Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695.
|
11279122 |
2001 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques.
|
26646366 |
2015 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
For the present study, we investigated whether IL-4 and IL-13 could activate microglial cells to induce Aβ clearance in vivo and improve cognitive deficits in APP23 mice, which are amyloid precursor protein transgenic mice.
|
22342341 |
2012 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota.
|
30816709 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Further, AS2715348 significantly ameliorated cognitive deficits in APP-transgenic Tg2576 mice.
|
24373902 |
2014 |